Exhibitors:Company Profile
The National Centre for Education and Training on Addiction (NCETA) is an internationally recognised research centre that works as a catalyst for change in the alcohol and other drugs (AOD) field.

NCETA is a collaborative venture between Flinders University and the Australian Government Department of Health and is located within the School of Medicine at Flinders University in South Australia.
The ATDC is the peak body representing and supporting community organisations, and the people they assist, to reduce alcohol, tobacco and other drug related harm for all Tasmanians.

Our vision is a Tasmania without alcohol, tobacco or other drug related harm or discrimination.
Biomed is one of the few pharmaceutical companies that continue to manufacture in New Zealand and employ kiwis.

We continue to operate a fully fledged injection production plant. The company offers a comprehensive range of products such as IV fluids, PCA's, epidurals, intrathecal bags and syringes.

Our CAPS department compounds a full range of TPN customised for the local market.
Drug and Alcohol Nurses of Australasia, DANA, is the peak organisation in Australasia nurses and midwives with a professional interest in Alcohol and Other Drug (AOD) issues.

DANA aims for excellence in all practice contexts. DANA welcomes others who share the aims of DANA, to promote collaborative partnerships that aim to achieve similar goals.

DANA actively promotes a role for nurses and midwives to respond to AOD related issues. In doing so, DANA promotes practice based on the best available evidence, and promotes active involvement in research into AOD related interventions, and other issues relevant to this field.
Insight is a specialist provider of alcohol and drug training, education, clinical resources and practice advice for workers and services. Our mission is to build a capable, confident and connected AOD workforce.
Anglicare is a state wide organisation supporting people with varying needs. We care about people whose lives are being affected by alcohol and other drugs. We provide a comprehensive range of services to support individuals and families impacted by alcohol and other drugs. Our support is free and confidential.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Our heritage in Australia reaches back more than 75 years and we employ more than 225 people here with a focus on Immunology, Liver Disease, Neuroscience and Oncology, and our therapies currently benefit more than 32,000 Australians.
The Australian Institute of Health and Welfare (AIHW) provides high-quality and independent evidence—used by many to improve policies and services on health and welfare issues and topics, including expenditure, hospitals, disease, injury, mental health, ageing, alcohol and other drugs, homelessness, housing, the disability, child protection, and the needs of Aboriginal and Torres Strait Islander people.
Gilead’s mission is to advance patient care by developing therapeutics to treat life-threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions including Haematology/Oncology (ZYDELIG® [idelalisib]), HIV (DESCOVY® [emtricitabine/tenofovir alafenamide], GENVOYA® [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide], STRIBILD® [tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat], EVIPLERA® [tenofovir disoproxil fumarate & emtricitabine & rilpivirine], ATRIPLA® [tenofovir disoproxil fumarate & emtricitabine & efavirenz], TRUVADA® [emtricitabine & tenofovir disoproxil fumarate], EMTRIVA® [emtricitabine], VIREAD® [tenofovir disoproxil fumarate]), chronic hepatitis B (VIREAD® [tenofovir disoproxil fumarate], HEPSERA® [adefovir dipivoxil]), chronic hepatitis C (EPCLUSA® [sofosbovir/velpatasvir], HARVONI® [ledipasvir & sofosbovir], SOVALDI® [sofosbuvir]), and systemic fungal infections (AmBisome® [liposomal amphotericin B])
The Australian Department of Health funded National Comorbidity Guidelines provides evidence-based information, training and resources to assist with the management of co-occurring, or comorbid, alcohol and other drug and mental health conditions. The Guidelines were developed by researchers from the Matilda Centre for Research in Mental Health and Substance Use in consultation with clinicians, consumers, carers and researchers.
The Australian Indigenous Knowledge Centre’s website contributes to improving the health of Australia’s Aboriginal and Torres Strait Islander peoples and assist in helping to close the gap by providing the evidence base to help reduce the harmful use of alcohol and other drugs.
Mundipharma is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products.
Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds as well as skin irritations.
Established in 2005, Healthe Care Australia has since grown to become a leading pan-Asian healthcare services group. We are one of the largest private mental health providers, offering near 800 beds across 15 facilities throughout Australia. We provide the necessary support, education programs and individual treatment plans to help people on the road to recovery and wellness.
Our specialty offerings include addictive disorders, adolescents, ambulatory programs, neurostimulation, older persons, perinatal disorders, PTSD programs for defence and emergency services, regional services, trauma and dissociation. Our innovation in service delivery includes acute community care, an assessment and intake model, and consultation-liaison services.
Pharmasea International produces iDoseTM, Australasia’s leading management system for the delivery of opioid substitution treatments in institutional settings. The iDoseTM system has been available for over 20 years and is continuously being developed and improved to ensure safe, professional and compliant delivery of OST services.
Pharmasea International is committed to providing high service levels and fast response its clients.
Camurus is a Swedish research-based pharmaceutical company committed to developing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the proprietary lipid-based FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of opioid dependence, pain, cancer and endocrine diseases, developed in-house and in collaboration with international pharmaceutical companies.
APSAD is the Asia Pacific’s leading multidisciplinary organisation for professionals involved in the alcohol and other drug field. APSAD is dedicated to increasing the profile of the issues related to the use of alcohol and other drugs, through the dissemination of information from the wide range of professions involved in this field.
The eMHPrac e-Mental Health in Practice Project is funded by the Australian Government and aims to raise health practitioner awareness and knowledge of digital mental health and to provide free training and support to GPs, Allied Health Professionals and service providers working with Aboriginal and Torres Strait Islander people. eMHPrac is a collaboration between QUT, Black Dog Institute, Menzies School of Health Research and University Centre for Rural Health, University of Sydney.
Breakthroughs that change patients’ lives™
Throughout Pfizer's 170 year history, and over 60 years in Australia, we have remained dedicated to discovering and developing new and better ways to prevent and treat disease, and improve the health and wellbeing of people around the world.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.
For more information visit www.pfizer.com.au
Indivior is the world leader in addiction treatment with over 20 years’ experience and a unique patient‐focused approach. Our endeavour is to understand the journey of individuals suffering with addiction.

We partner with healthcare professionals, the public health community, policymakers, and payers to ensure people suffering from addiction are treated just like any other patients suffering from a chronic, relapsing medical condition.

At Indivior our endeavour is to focus on individual patients around the world. The patient continues to drive our decisions.

Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision of ensuring unrestricted access to high‐quality treatments for the chronic relapsing conditions and co-morbidities of addiction.